Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

被引：43

作者：

Dorrell, Lucy ^{[1
]}

Williams, Patricia ^{[1
]}

Suttill, Annie ^{[1
]}

Brown, Denise ^{[1
]}

Roberts, Joanna ^{[1
]}

Conlon, Christopher ^{[1
]}

Hanke, Tomas ^{[1
]}

McMichael, Andrew ^{[1
]}

机构：

[1] John Radcliffe Hosp, Weatherrall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England

来源：

VACCINE | 2007年 / 25卷 / 17期

基金：

英国医学研究理事会;

关键词：

modified vaccinia virus Ankara; HIV-1; clinical study;

D O I：

10.1016/j.vaccine.2007.01.005

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in their application as vaccine vectors, first, because new HIV-1 infections may occur in vaccine trials involving persons at high risk of infection and secondly, therapeutic vaccinations are a potential means to enhance virus-specific immune responses once infection has occurred. We administered a candidate modified vaccinia virus Ankara-vectored HIV-1 vaccine, MVA.HIVA, by intradermal injection to 16 chronically infected adults during highly active antiretroviral therapy. Vaccinations were well tolerated and there were no serious adverse events. No breakthrough viraemia occurred after immunisations or throughout follow-up. These data confirm the safety of MVA.HIVA in HIV-1-infected individuals and provide Support for further evaluation of MVA-vectored vaccines in prophylactic and therapeutic immunisation strategies. (c) 2007 Elsevier Ltd. All rights reserved.

引用

收藏

页码：3277 / 3283

页数：7

相关论文

共 36 条

[1] Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya [J].

Bejon, P ;

Peshu, N ;

Gilbert, SC ;

Lowe, BS ;

Molyneux, CS ;

Forsdyke, J ;

Lang, T ;

Hill, AVS ;

Marsh, K .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (08) :1102-1110

[2] Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:: implications for use as a human vaccine [J].

Blanchard, TJ ;

Alcamí, A ;

Andrea, P ;

Smith, GL .

JOURNAL OF GENERAL VIROLOGY, 1998, 79 :1159-1167

[3] Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers [J].

Cebere, I ;

Dorrell, L ;

McShane, H ;

Simmons, A ;

McCormack, S ;

Schmidt, C ;

Smith, C ;

Brooks, M ;

Roberts, JE ;

Darwin, SC ;

Fast, PE ;

Conlon, C ;

Rowland-Jones, S ;

McMichael, AJ ;

Hanke, T .

VACCINE, 2006, 24 (04) :417-425

[4] Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals [J].

Cosma, A ;

Nagaraj, R ;

Bühler, S ;

Hinkula, J ;

Busch, DH ;

Sutter, G ;

Goebel, FD ;

Erfle, V .

VACCINE, 2003, 22 (01) :21-29

[5] Therapeutic immunization strategies for the control of HIV-1 [J].

Dorrell, L .

EXPERT REVIEW OF VACCINES, 2005, 4 (04) :513-520

[6] Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients:: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine [J].

Dorrell, L ;

Yang, HB ;

Iversen, AKN ;

Conlon, C ;

Suttill, A ;

Lancaster, M ;

Dong, T ;

Cebere, I ;

Edwards, A ;

Rowland-Jones, S ;

Hanke, T ;

McMichael, AJ .

AIDS, 2005, 19 (12) :1321-1323

[7] Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine [J].

Dorrell, Lucy ;

Yang, Hongbing ;

Ondondo, Beatrice ;

Dong, Tao ;

di Gleria, Kati ;

Suttill, Annie ;

Conlon, Christopher ;

Brown, Denise ;

Williams, Patricia ;

Bowness, Paul ;

Goonetilleke, Nilu ;

Rostron, Tim ;

Rowland-Jones, Sarah ;

Hanke, Tomas ;

McMichael, Andrew .

JOURNAL OF VIROLOGY, 2006, 80 (10) :4705-4716

[8] Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells [J].

Drexler, I ;

Heller, K ;

Wahren, B ;

Erfle, V ;

Sutter, G .

JOURNAL OF GENERAL VIROLOGY, 1998, 79 :347-352

[9] Modified vaccinia virus Ankara induces moderate activation of human dendritic cells [J].

Drillien, R ;

Spehner, D ;

Hanau, D .

JOURNAL OF GENERAL VIROLOGY, 2004, 85 :2167-2175

[10]

Florence E, 2003, HIV Med, V4, P255, DOI 10.1046/j.1468-1293.2003.00156.x

← 1 2 3 4 →